Clinical Trial Update: Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/2 dose-ranging study of ST-920, an AAV2/6-based gene therapy delivering alpha-galactosidase A for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• ST-920

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Fabry Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-04-14